Abstract
Objectives
SARS-CoV-2 virus and its variants continue to be on a rampage worldwide. Several vaccines are being marketed to control their spread and reduce severity of symptoms in the affected. Various adverse events are being reported following the vaccine administration and therefore this systematic review investigated the oral adverse events post-COVID-19 vaccination.
Materials and methods
A systematic search of five databases was conducted. Case reports, case series and observational studies describing oral lesions/oral adverse effects (outcome) following anti-SARS-CoV-2 vaccination (exposure) in humans were included. Quality assessment of the studies was done using Joanna Briggs Institute Critical Appraisal tools. A working classification was developed from reported final diagnosis.
Results
The systematic review included 18 individual cases. Majority of oral lesions occurred following BNT162b2 vaccination with average age of occurrence at 59.94 years. 67% of the affected individuals were female, with hypertension being the most common comorbidity.
Discussion
Immune-mediated oral events have a propensity of occurrence following COVID-19 vaccination. mRNA-based vaccinations may have an affinity for causing oral adverse effects. It might be due to the immune dysregulation caused by these vaccinations.
Conclusion
The female, geriatric population and older individuals with co-morbidities might have an increased affinity to develop oral lesions post-COVID-19 vaccination.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The data is available on request to corresponding author.
References
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21:626–36.
Hadj Hassine I. Covid‐19 vaccines and variants of concern: a review. Rev Med Virol. 2022;32:e2313.
Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis Elsevier. 2022;22:1002–10.
Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12:714170.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. Br Med J Publishing Group; 2021;372:n71.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic reviews of etiology and risk - JBI Manual for Evidence Synthesis - JBI Global Wiki [Internet]. [cited 2023 Mar 18]. Available from: https://jbi-global-wiki.refined.site/space/MANUAL/4687372/Chapter+7%3A+Systematic+reviews+of+etiology+and+risk.
Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18:2127.
Torrealba-Acosta G, Martin JC, Huttenbach Y, Garcia CR, Sohail MR, Agarwal SK, et al. Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine. BMJ Case Rep. 2021;14:e243173.
Petruzzi M, Galleggiante S, Messina S, della Vella F. Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases. BMC Oral Health. 2022;22:90.
Vaira LA, Podda L, Doneddu P, Careddu MG, Fozza C, De Riu G. Secondary thrombocytopenia after SARS-CoV-2 vaccine: Report of a case of hemorrhage and hematoma after minor oral surgery. J Stomatol Oral Maxillofac Surg. 2022;123:95–7.
Chun Y, Jang J, Jo JH, Park JW. Various painful oral adverse reactions following COVID-19 vaccination: a case series. BMC Oral Health. 2022;22:64.
Sayare B, Bhardwaj VK, Sharma D. Palatal petechiae: an uncommon oral adverse effect of COVID-19 vaccine. Egypt J Otolaryngol. 2021;37:99.
Bakir M, Almeshal H, Alturki R, Obaid S, Almazroo A. Toxic epidermal necrolysis post COVID-19 vaccination - first reported case. Cureus. 2021;13:e17215.
Babazadeh A, Miladi R, Barary M, Shirvani M, Ebrahimpour S, Aryanian Z, et al. COVID-19 vaccine-related new-onset lichen planus. Clin Case Rep. 2022;10:e05323.
Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open. 2021;4:e2140364.
Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326:1390–9.
Fiolet T, Kherabi Y, MacDonald C-J, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28:202–21.
ElSawi HA, Elborollosy A. Immune-mediated adverse events post-COVID vaccination and types of vaccines: a systematic review and meta-analysis. Egypt J Intern Med. 2022;34:44.
Sood A, Raghavan S, Batra P, Sharma K, Talwar A. Rise and exacerbation of oral lichen planus in the background of SARS-CoV-2 infection. Med Hypotheses. 2021;156:110681.
Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021;6:104.
Khavinson V, Terekhov A, Kormilets D, Maryanovich A. Homology between SARS CoV-2 and human proteins. Sci Rep. 2021;11:17199.
National Institute of Allergy and Infectious Diseases (NIAID). Analysis of the Immune Response to COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations [Internet]. clinicaltrials.gov; 2023 Feb. Report No.: NCT04852276. Available from: https://clinicaltrials.gov/ct2/show/NCT04852276.
Gambichler T, Boms S, Susok L, Dickel H, Finis C, Abu Rached N, et al. Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol. 2022;36:172–80.
Riad A, Põld A, Kateeb E, Attia S. Oral adverse events following COVID-19 vaccination: analysis of VAERS reports. Front Public Health. 2022;10:952781.
Hertel M, Heiland M, Nahles S, von Laffert M, Mura C, Bourne PE, et al. Real‐world evidence from over one million COVID‐19 vaccinations is consistent with reactivation of the varicella‐zoster virus. J Eur Acad Dermatol Venereol. 2022;36:1342–8.
Akpandak I, Miller DC, Sun Y, Arnold BF, Kelly JD, Acharya NR. Assessment of herpes zoster risk among recipients of COVID-19 vaccine. JAMA Netw Open. 2022;5:e2242240.
Di Spirito F, Amato A, Di Palo MP, Contaldo M, D’Ambrosio F, Lo Giudice R, et al. Oral lesions following anti-SARS-CoV-2 vaccination: a systematic review. Int J Environ Res Public Health. 2022;19:10228.
Kronzer VL, Bridges SL, Davis JM. Why women have more autoimmune diseases than men: an evolutionary perspective. Evol Appl. 2020;14:629–33.
Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35:347–69.
Kaye AD, Okeagu CN, Pham AD, Silva RA, Hurley JJ, Arron BL, et al. Economic impact of COVID-19 pandemic on healthcare facilities and systems: International perspectives. Best Pract Res Clin Anaesthesiol. 2021;35:293–306.
Russell MW, Mestecky J. Mucosal immunity: the missing link in comprehending SARS-CoV-2 infection and transmission. Front Immunol. 2022;13:957107.
Wahl I, Wardemann H. Sterilizing immunity: understanding COVID-19. Immunity. 2022;55:2231–5.
Miteva D, Peshevska-Sekulovska M, Snegarova V, Batselova H, Alexandrova R, Velikova T. Mucosal COVID-19 vaccines: risks, benefits and control of the pandemic. World J Virol. 2022;11:221–36.
King’s College London. Role of the Oral Microbiome & Mucosal Immunity in COVID-19 Disease: Diagnostic/Prognostic Utility in South Asian Populations [Internet]. clinicaltrials.gov; 2022 Jan. Report No.: NCT05212766. Available from: https://clinicaltrials.gov/ct2/show/NCT05212766.
Funding
The author(s) received no specific funding for this work.
Author information
Authors and Affiliations
Contributions
Conceptualization: [Anubhuti Sood]; Methodology: [Anubhuti Sood and Harsh Priya]; Formal analysis and investigation: [Anubhuti Sood, Harsh Priya, Sreevatsan Raghavan and Deepika Mishra]; Writing—original draft preparation: [Anubhuti Sood]; Writing—review and editing: [Sreevatsan Raghavan, Harsh Priya and Deepika Mishra]; Supervision: [Harsh Priya and Deepika Mishra].
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Sood, A., Raghavan, S., Mishra, D. et al. Effects of post-COVID-19 vaccination in oral cavity: a systematic review. Evid Based Dent (2024). https://doi.org/10.1038/s41432-024-01014-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41432-024-01014-6